Clinical Trials for Hansoh Pharmaceutical

A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone

A Phase 3 Study of HS-20094 in Patients With T2DM

Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis

A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10510 in Healthy Subjects

Two Different Regiments of Pegmolesatide for Anemia in Patients With Chronic Kidney Disease Not Receiving Dialysis

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118

HS-10542 Study in Healthy Participants

A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors

HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118

A Study of HS-20094 in Overweight or Obese Participants

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.

Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function

Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function

A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

A Study of HS-20094 in Chinese Adults with Overweight or Obesity

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

A Study Evaluating Food Effect on Pharmacokinetics of HS-10518

Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)

A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

Phase 1 Study in Healthy Participants and Participants With Kidney Dysfunction

Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder

The Phase I Study of HS-10509 in Chinese Adult Subjects

A Study of HS-10501 Tablets in Healthy Subjects

A Study of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)

A Trial of HS-10511 in Healthy Subjects

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

A Study of HS-10518 in Healthy Female Participants

A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

A Phase II Study of HS-10353 in Participants With Postpartum Depression

A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors

MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.

The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.

Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer

Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors

Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases

Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma